Ligand Pharmaceuticals (LGND) Return on Capital Employed (2011 - 2026)

Ligand Pharmaceuticals has disclosed Return on Capital Employed across 16 years of filings, most recently posting 6.28% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 6.28%, up 1343.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 6.28% (up 1343.0% YoY), and the FY2025 annual result was 3.38%, up 611.0% from the prior year.
• Return on Capital Employed came in at 6.28% for Q1 2026 at Ligand Pharmaceuticals, up from 2.77% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 8.74% in Q1 2022 to a low of 7.15% in Q1 2025.
• The 5-year median for Return on Capital Employed is 0.59% (2023), against an average of 1.15%.
• Across the five-year window, Return on Capital Employed plunged 797 bps in 2022 and surged 1343 bps in 2026, its largest moves.
• Ligand Pharmaceuticals' Return on Capital Employed stood at 0.38% in 2022, then surged by 317 bps to 1.57% in 2023, then plunged by 258 bps to 2.48% in 2024, then soared by 212 bps to 2.77% in 2025, then jumped by 127 bps to 6.28% in 2026.
• The last three Return on Capital Employed figures came in at 6.28% (Q1 2026), 2.77% (Q4 2025), and 1.48% (Q3 2025), per Business Quant data.